Table III.
Comparison of PGI, PGII, G-17 levels and the PGI:II ratio between subjects with histological non CAG, CAG, IM and gastric adenocarcinoma.
| Histological finding | |||||
|---|---|---|---|---|---|
| Serum biomarker | Non CAG (n=48) | CAG (n=12) | IM (n=9) | Gastric adenocarcinoma (n=3) | P-valuea |
| PG I, µg/l | 138.9 (98.0–218.0) | 108.7 (47.5–167.2) | 116.6 (76.9–167.2) | 191.3 | 0.261 |
| P-valueb | 0.100 | 0.175 | 0.925 | ||
| PG II, µg/l | 10.2 (6.0–12.7) | 7.7 (5.8–12.4) | 10.9 (8.3–13.1) | 17.6 | 0.096 |
| P-valueb | 0.657 | 0.470 | 0.012c | ||
| PGI:II ratio | 15.7 (11.4–19.2) | 10.1 (6.5–16.2) | 12.0 (8.6–15.4) | 3.8 | 0.016c |
| P-valueb | 0.027c | 0.031c | 0.075 | ||
| G-17, pmol/l | 3.75 (1.4–11.9) | 6.75 (2.8–57.4) | 5.1 (2.3–15.1) | 0.9 | 0.311 |
| P-valueb | 0.074 | 0.031 | 0.555 | ||
Data are provided as medians with interquartile range.
a
Kruskal-Wallis test
b
Mann-Whitney U test vs. histological non CAG
c
P<0.05 vs. histological non CAG. PG, pepsinogen; CAG, chronic atrophic gastritis; IM, intestinal metaplasia; G-17, gastrin-17; SD, standard deviation.